Peplin is a development stage specialty pharmaceutical company focused on advancing and commercializing medical dermatology products. Peplin advanced PEP005, a patient-applied topical gel containing ingenol mebutate, into Phase 3 trials for the treatment of actinic keratosis.
Missing: Peplin's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Peplin's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Latest Peplin News
Sep 15, 2021
American Skin Association Announces New Board Member Eugene A. Bauer, MD NEW YORK, Sept. 15, 2021 /PRNewswire/ -- American Skin Association (ASA) today announced that Eugene Bauer, MD, will join its Board of Directors. Author: Sep 15, 2021 11:36 AM EDT NEW YORK, Sept. 15, 2021 /PRNewswire/ -- American Skin Association (ASA) today announced that Eugene Bauer, MD, will join its Board of Directors. He is immediate past co-founder, Chief Medical Officer, and member of the Board of Directors of Dermira, Inc., a biotechnology company recently acquired by Eli Lilly and Company. "We are proud to announce the addition of Dr. Eugene Bauer to ASA's Board of Directors. Dr. Bauer's experience in both dermatology and the pharmaceutical industry will be a tremendous asset to our board," said Howard P. Milstein, Chairman of ASA. "Dr. Bauer is a wonderful addition to our Board of Directors! We look forward to working with him as we continue to work towards our vital mission and provide hope to those suffering from skin diseases," said Dr. David Norris, President of ASA. Before initiating a career in the pharmaceutical industry, Dr. Bauer served as Chairman of the Department of Dermatology (1988-1995) and as the Dean of the School of Medicine (1995-2001) of Stanford University. He was a National Institutes of Health (NIH)-funded investigator for 25 years and has served on numerous advisory groups for the NIH. He has been elected to several honorific societies, including the National Academy of Medicine of the United States. Prior to founding Dermira, Dr. Bauer served as a member of the board of directors of Peplin, Inc., where he also was its President and Chief Medical Officer, until Peplin's acquisition by LEO Pharma in 2009. During 2004-2008, Dr. Bauer was Chief Executive Officer of Neosil, Inc., a clinical-stage dermatology company, acquired by Peplin, Inc., in 2008. Prior to that, he was co-founder and member of the Board of Directors at Connetics, a commercial dermatology company. ABOUT AMERICAN SKIN ASSOCIATIONASA is a unique collaboration of patients, families, advocates, physicians and scientists, and has evolved over thirty-four years into a leading force in efforts to defeat melanoma, skin cancer and important inflammatory and genetic skin diseases. Established to serve the now more than 100 million Americans - one third of the U.S. population - afflicted with skin disorders, the organization's mission remains to: advance research, champion skin health - particularly among children, and drive public awareness about skin disease. For more information, visit American Skin Association View original content to download multimedia: https://www.prnewswire.com/news-releases/american-skin-association-announces-new-board-member-eugene-a-bauer-md-301377815.html SOURCE American Skin Association
Peplin Frequently Asked Questions (FAQ)
Where is Peplin's headquarters?
Peplin's headquarters is located at 6475 Christie Avenue, Parsippany.
What is Peplin's latest funding round?
Peplin's latest funding round is Dead.
How much did Peplin raise?
Peplin raised a total of $20.53M.
Who are the investors of Peplin?
Investors of Peplin include LEO Pharma, MPM Capital, Orbis Investment Management, Asia Union Investments Pty., New Enterprise Associates and 7 more.
Who are Peplin's competitors?
Competitors of Peplin include ISA Pharmaceuticals, Esperance Pharmaceuticals, Aegerion Pharmaceuticals, NellOne Therapeutics, Activate Immunotherapy and 12 more.
Compare Peplin to Competitors
Theraclone Sciences, formerly Spaltudaq, is a biotechnology company focused on the development of novel therapeutic antibodies for the treatment of infectious disease and cancer. The companys technology harnesses the power of the human immune system to identify rare, naturally evolved antibodies from the blood cells of immunologically relevant human subjects. Human monoclonal antibodies can be rapidly isolated using the ISTAR discovery platform and scaled for industrial production. Such human antibody drug candidates may be uniquely safe and relevant to combating disease across broad patient populations.
Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.
Onyvax is developing new cancer therapies that harness the selective power of the immune system to seek out and destroy tumor cells. Onyvax's products specifically target cancer cells, increasing the likelihood that they will be effective while minimising side effects associated with many conventional treatments. These therapies can broadly be classed as therapeutic cancer vaccines. Onyvax's lead product is in clinical trials for the treatment of prostate cancer and is poised to enter the final stages of development. Onyvax is committed to the commercialisation of therapies that enhance survival while maintaining a high quality of life for patients. The Company is based in London and has collaborations with leading hospitals and other institutions throughout Europe and the US.
ISA Pharmaceuticals develops treatments for various cancers and infectious diseases. It focuses on the development of synthetic peptide vaccines that boost the immune system to recognize specific peptides associated with specific types of cancer and subsequently destroy the tumor cells. The company was founded in 2004 and is based in Oestgeest, Netherlands.
Juventas Therapeutics, formerly AcelleRx Therapeutics, Juventas Therapeutics is a privately held, clinical stage biotechnology company focused on developing non-viral gene therapies to treat advanced cardiovascular diseases. The Company's lead product candidate, JVS-100, is a non-viral gene therapy undergoing evaluation in clinical studies for the treatment of advanced cardiovascular diseases.
Harkness Pharmaceuticals is focused on developing anti-obesity therapeutics. Per the company, currently more than 20% of the U.S. population are considered clinically obese yet there remain few therapeutic option available. Harkness is performing exploratory human clinical trials in collaboration with the Pennington Institute in Louisiana.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.